Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

ZURA

Zura Bio Ltd

Apr 23 • 01:09PM ET

3.51

Dollar change +0.20
Percentage change 6.04	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: VXF IWM IWN SCHA VTWO IWC OMFS VTWV SCHB URTY

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-4.39	Insider Own	56.64%	Shs Outstand	43.59M	Perf Week	15.46%
Market Cap	153.00M	Forward P/E	-	EPS next Y	-1.18	Insider Trans	-7.49%	Shs Float	18.90M	Perf Month	71.22%
Income	-69.24M	PEG	-	EPS next Q	-0.26	Inst Own	45.97%	Short Float	3.32%	Perf Quarter	-11.81%
Sales	0.00M	P/S	-	EPS this Y	50.56%	Inst Trans	2.60%	Short Ratio	2.17	Perf Half Y	-24.03%
Book/sh	1.36	P/B	2.58	EPS next Y	-13.87%	ROA	-	Short Interest	0.63M	Perf Year	-58.71%
Cash/sh	2.29	P/C	1.53	EPS next 5Y	-	ROE	-	52W Range	2.00 - 14.00	Perf YTD	-24.84%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-116.71%	52W High	-74.93%	Beta	0.33
Dividend TTM	-	Quick Ratio	4.97	Sales past 5Y	0.00%	Gross Margin	-	52W Low	75.50%	ATR (14)	0.38
Dividend Ex-Date	-	Current Ratio	4.97	EPS Y/Y TTM	-2148.09%	Oper. Margin	0.00%	RSI (14)	58.61	Volatility	11.86% 15.39%
Employees	15	Debt/Eq	0.00	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	19.33
Option/Short	No / Yes	LT Debt/Eq	0.00	EPS Q/Q	-641.35%	Payout	-	Rel Volume	0.39	Prev Close	3.31
Sales Surprise	-	EPS Surprise	40.57%	Sales Q/Q	-	Earnings	Mar 28 BMO	Avg Volume	289.36K	Price	3.51
SMA20	20.87%	SMA50	8.03%	SMA200	-28.24%	Trades		Volume	66,528	Change	6.04%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-10-23	Initiated	Ladenburg Thalmann	Buy	$10
Aug-25-23	Initiated	Oppenheimer	Outperform	$17
Jun-22-23	Initiated	Guggenheim	Buy	$20
Jun-14-23	Initiated	Chardan Capital Markets	Buy	$14
May-24-23	Initiated	Raymond James	Strong Buy	$20

Apr-18-24 09:22AM	Zura Bio Announces Oversubscribed $112.5 Million Private Placement (Business Wire) +17.89%
Apr-08-24 06:00AM	Zura Bio Announces Robert Lisicki as CEO and Director (Business Wire)
Mar-28-24 11:54AM	ZURA Stock Earnings: Zura Bio Misses EPS for Q4 2023 (InvestorPlace) +10.78%
06:00AM	Zura Bio Reports Full Year 2023 Financial Results, Business Highlights, and Appoints Robert Lisicki as Chief Executive Officer (Business Wire)
Mar-04-24 06:00AM	Zura Bio Announces Participation at March Conferences (Business Wire)
06:00AM	Loading…
Feb-02-24 06:00AM	Zura Bio Announces Participation at February Investor Conferences (Business Wire) +6.11%
Jan-08-24 06:00AM	Zura Bio Continues to Strengthen Leadership with Appointment of Robert Lisicki as President and Kiran Nistala as CMO (Business Wire)
Jan-03-24 06:00AM	Zura Bio to Present at the 42nd Annual J.P. Morgan Healthcare Conference and Dermatology Summit (Business Wire)
Dec-04-23 06:00AM	Zura Bio Announces Two Immunology Abstracts Presented at the World Allergy Congress in Bangkok (Business Wire)
Nov-14-23 06:00AM	Zura Bio Appoints Arnout Ploos van Amstel to its Board of Directors (Business Wire) +10.00%
Nov-13-23 06:30AM	Zura Bio Reports Third Quarter 2023 Financial Results and Recent Business Highlights (Business Wire) -6.54%
Sep-12-23 05:00AM	Zura Bio Enters into Sponsored Research Agreement with Benaroya Research Institute (Business Wire)
Sep-05-23 08:55PM	Oppenheimer Says These 2 Stocks Could Double Your Money Heres Why They Could Jump (TipRanks)
Aug-25-23 09:42AM	Netflix upgraded, Olaplex downgraded: Wall Street's top analyst calls (The Fly)
Aug-14-23 07:00AM	Zura Bio Reports Second Quarter 2023 Financial Results and Recent Business Highlights (Business Wire)
06:30AM	Loading…
Jun-23-23 06:30AM	Zura Bio to Join the Russell 2000® and Russell 3000® Indexes (Business Wire) -5.69%
Jun-06-23 06:34AM	Daily Vickers Top Buyers & Sellers for 06/06/2023 (Argus Research) +16.80%
04:00AM	Zura Bio Completes Approximately $80 Million Financing with the Focus on Advancing ZB-106, a Potential First-in-class Anti-IL-17 and Anti-BAFF Dual Antagonist (Business Wire)
Jun-01-23 10:20AM	Load Up, Says Raymond James About These 2 Strong Buy Stocks (TipRanks) +10.82%
Apr-27-23 07:39AM	Zura Bio Announces $80 Million Financing and the Licensing of Tibulizumab (ZB-106), a Potential First-in-Class anti-IL-17 and anti-BAFF Dual Antagonist for Autoimmune Diseases (Business Wire)
Apr-14-23 05:00AM	Zura Bio Announces Appointment of Chief Scientific Officer (Business Wire)
Mar-27-23 09:35AM	Zura Bio Limited Announces Share Redemptions and Lock-up Agreement (Business Wire) -42.76%
Mar-21-23 06:13AM	Zura Bio Limited Announces Closing of Business Combination with JATT Acquisition Corp (Business Wire) -11.27%

Zura Bio Ltd. is a clinical-stage biotechnology company that engages in the development of novel medicines for immune disorders. It focuses on the development of ZB-168, a treatment for Alopecia Areata and other inflammatory diseases. The company was founded by Someit Sidhu on January 18, 2022 and is headquartered in Henderson, NV.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Thiara Parvinder	Director	Dec 12 '23	Sale	4.00	2,000,000	8,000,000	4,801,633	Dec 14 03:35 PM
Munshi Amit	Director	Jun 05 '23	Buy	4.25	117,647	500,000	617,640	Jun 05 07:15 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ZURA

Zura Bio Ltd

Upgrade your FINVIZ experience